Figure 4

The effect of 113 μM I3C, 2.30 μM sorafenib and their combination on the levels of (A) p-Akt, (B) p-ERK and (C) HIF-1α. Data is given as percentage of control. Each point is the mean ± SD of 3 independent experiments. a or b: Significantly different from the control or sorafenib group, respectively, p < 0.05 using ANOVA followed by Tukey–Kramer as post-hoc test.